LQDA · Company research
Liquidia Corporation (LQDA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
30records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation - Yahoo Finance | Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Liquidia (LQDA) Stock Looks Fairly Valued After A Big Run - Simply Wall Street | Liquidia (LQDA) Stock Looks Fairly Valued After A Big Run Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring - Yahoo Finance | What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option Buying - MarketBeat | Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option Buying MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label | Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - TradingView | LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label TradingView | View source ↗ | TradingView | Oct 14, 2026 | neutral | 0 | 0.6 |
| LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’ - Stocktwits | LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’ Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Liquidia shares surge to 5-month high premarket on United Therapeutics settlement - Yahoo Finance | Liquidia shares surge to 5-month high premarket on United Therapeutics settlement Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Biggest stock movers Wednesday: DELL, LQDA, ENVX and more (BAC:NYSE) - Seeking Alpha | Biggest stock movers Wednesday: DELL, LQDA, ENVX and more (BAC:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| Liquidia (NASDAQ:LQDA) Stock: Insider Sanjeev Khindri Sells 1,101 Shares - MarketBeat | Liquidia (NASDAQ:LQDA) Stock: Insider Sanjeev Khindri Sells 1,101 Shares MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| To cover award taxes, Dana Boyle sells 5,892 Liquidia (LQDA) shares at $28.48 each. - Stock Titan | To cover award taxes, Dana Boyle sells 5,892 Liquidia (LQDA) shares at $28.48 each. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan | Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky - PR Newswire | Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Oct 12, 2026 | neutral | 0 | 0.6 |
| Liquidia (NASDAQ:LQDA) Shares Gap Up - Here's Why - MarketBeat | Liquidia (NASDAQ:LQDA) Shares Gap Up - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Liquidia (NasdaqCM:LQDA) Stock Forecast & Analyst Predictions - Simply Wall Street | Liquidia (NasdaqCM:LQDA) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| Liquidia (LQDA) Board Member Sells $6.39M Shares, Stock Jumps 8. - GuruFocus | Liquidia (LQDA) Board Member Sells $6.39M Shares, Stock Jumps 8. GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire | Levi & Korsinsky Notifies Investors of Pending GlobeNewswire | View source ↗ | GlobeNewswire | Oct 8, 2026 | neutral | 0 | 0.6 |
| LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm | A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | neutral | 0 | 1 |
| Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access - Yahoo Finance | Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation - PR Newswire | LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation PR Newswire | View source ↗ | PR Newswire | Oct 6, 2026 | neutral | 0 | 0.6 |
| Liquidia (NASDAQ:LQDA) Stock Price Down 6.1% After Analyst Downgrade - MarketBeat | Liquidia (NASDAQ:LQDA) Stock Price Down 6.1% After Analyst Downgrade MarketBeat | View source ↗ | MarketBeat | Oct 5, 2026 | neutral | 0 | 0.6 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - TradingView | Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback TradingView | View source ↗ | TradingView | Oct 1, 2026 | neutral | 0 | 0.6 |
| UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% | United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% | United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path - Stocktwits | LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path Stocktwits | View source ↗ | Stocktwits | Oct 1, 2026 | neutral | 0 | 0.6 |
| Liquidia plunges after court ruling in United Therapeutics patent fight (LQDA:NASDAQ) - Seeking Alpha | Liquidia plunges after court ruling in United Therapeutics patent fight (LQDA:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 30, 2026 | neutral | 0 | 0.6 |
| A court found Liquidia infringed two patent claims. Its inhaled treatment could face limits. - Stock Titan | A court found Liquidia infringed two patent claims. Its inhaled treatment could face limits. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims - Stocktwits | LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims Stocktwits | View source ↗ | Stocktwits | Sep 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.